Vivos (RDGL) Capital Expenditures (2010 - 2017)

Vivos (RDGL) reported Capital Expenditures of $2800.0 for Q1 2017, down 71.29% sequentially from $9754.0 in Q1 2013.

Vivos (RDGL) Capital Expenditures (2010 - 2017) Analysis & Trends

Vivos (RDGL) has 4 years of Capital Expenditures data on file, last reported at $2800.0 in Q1 2017.

For the quarter ending Q1 2017, Capital Expenditures changed N/A year-over-year to $2800.0; the trailing twelve-month figure through Mar 2017 stood at -$72124.0 (changed N/A YoY), and the FY2025 full-year result was $103185.0, changed N/A from the prior year.
Capital Expenditures slipped to $2800.0 in Q1 2017, from $9754.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $9754.0 in Q1 2013 to a low of $2800.0 in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	399.00 Mn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	166.00 Mn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	177.00 Mn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	64.90 Mn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	76.60 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	178.00 Mn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	-85.46 Mn
10	Vivos	27.16 Mn	25.60 Mn	-3,105.00	-

Download Data